The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II trial comparing docetaxel with or without low-dose metronomic oral cyclophosphamide in first-line treatment of non-triple-negative advanced breast cancer.
Leiping Wang
No relevant relationships to disclose
Jian Zhang
No relevant relationships to disclose
Zhong Hua Wang
No relevant relationships to disclose
Biyun Wang
No relevant relationships to disclose
Jun Cao
No relevant relationships to disclose
Fangfang Lv
No relevant relationships to disclose
Sheng Zhang
No relevant relationships to disclose
Shao Zhimin
No relevant relationships to disclose
Xi-Chun Hu
No relevant relationships to disclose